<DOC>
	<DOC>NCT02242942</DOC>
	<brief_summary>This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The anticipated time on study treatment will be approximately one year and the follow-up period will be up to 5 years.</brief_summary>
	<brief_title>A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Documented previously untreated CLL according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria CLL requiring treatment according to IWCLL criteria Total Cumulative Illness Rating Scale (CIRS score) greater than (&gt;) 6 Adequate marrow function independent of growth factor or transfusion support within 2 weeks of screening as per protocol, unless cytopenia is due to marrow involvement of CLL Adequate liver function Life expectancy &gt; 6 months Agreement to use highly effective contraceptive methods per protocol Transformation of CLL to aggressive NonHodgkin's lymphoma (Richter's transformation or prolymphocytic leukemia) Known central nervous system involvement Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML) An individual organ/ system impairment score of 4 as assessed by the CIRS definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia Inadequate renal function History of prior malignancy, except for conditions as listed in the protocol if patients have recovered from the acute side effects incurred as a result of previous therapy Use of investigational agents or concurrent anticancer treatment within the last 4 weeks of registration Participants with active bacterial, viral, or fungal infection requiring systemic treatment within the last two months prior to registration History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products Hypersensitivity to chlorambucil, obinutuzumab, or venetoclax or to any of the excipients Pregnant women and nursing mothers Positive test results for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] serology) or positive test result for hepatitis C (hepatitis C virus [HCV] antibody serology testing) Participants with known infection with human immunodeficiency virus (HIV) or human Tcell leukemia virus1 (HTLV1) Requires the use of warfarin, marcumar, or phenprocoumon Received agents known to be strong and moderate Cytochrome P450 3A inhibitors or inducers within 7 days prior to the first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>